Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Breast 1

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 13Ovarian Neoplasms 5Prostatic Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pathologic Complete Response 1Mesothelioma 1Hemangiosarcoma 1Gastrointestinal Neoplasms 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Breast Adenocarcinoma 1Advanced Ovarian Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 8Carboplatin 6Cyclophosphamide 5veliparib 4olaparib 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Taxes 3Paclitaxel 3Gene Expression Profiling 3Gemcitabine 3palbociclib 2niraparib 2fludarabine 2durvalumab 2Temozolomide 2Specimen Handling 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Leucovorin 2Interleukin-2 2Fulvestrant 2Fluorouracil 2Early Intervention, Educational 2Drug Therapy 2Doxorubicin 2Biopsy 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × talazoparib × Breast × Clear all
NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡